Otonomy Inc. (OTIC)

2.20
0.03 1.35
NASDAQ : Health Technology
Prev Close 2.23
Open 2.21
Day Low/High 2.20 / 2.24
52 Wk Low/High 1.50 / 3.15
Volume 29.39K
Avg Volume 50.10K
Exchange NASDAQ
Shares Outstanding 30.75M
Market Cap 68.88M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Otonomy Initiating Phase 1/2 Clinical Trial Of OTO-413 In Hearing Loss

Otonomy Initiating Phase 1/2 Clinical Trial Of OTO-413 In Hearing Loss

Results expected in second half of 2020

Otonomy Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Otonomy Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Clinical-stage programs on track with results expected from three trials in 2020 Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.

Otonomy To Report Second Quarter 2019 Financial Results And Provide Corporate Update

Otonomy To Report Second Quarter 2019 Financial Results And Provide Corporate Update

Webcast and Conference Call to be Held at 4:30 p.m. EDT on August 1, 2019

Oversold Conditions For Otonomy (OTIC)

Oversold Conditions For Otonomy (OTIC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Otonomy To Report Fourth Quarter And Full Year 2017 Financial Results And Provide Corporate Update

Otonomy To Report Fourth Quarter And Full Year 2017 Financial Results And Provide Corporate Update

Webcast and Conference Call to be Held at 4:30 p.m. EST on March 8, 2018

Otonomy Announces Multiple Presentations For Hearing Loss And Tinnitus Programs At Upcoming Association For Research In Otolaryngology Meeting

Otonomy Announces Multiple Presentations For Hearing Loss And Tinnitus Programs At Upcoming Association For Research In Otolaryngology Meeting

Data Support Potential of OTO-413 as a Treatment for Synaptopathy-Related Hearing Loss

Interesting OTIC Put And Call Options For February 2018

Interesting OTIC Put And Call Options For February 2018

Investors in Otonomy Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OTIC options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.

Otonomy Reports Third Quarter 2017 Financial Results And Provides Corporate Update

Otonomy Reports Third Quarter 2017 Financial Results And Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EST

Otonomy To Report Third Quarter 2017 Financial Results And Provide Corporate Update

Otonomy To Report Third Quarter 2017 Financial Results And Provide Corporate Update

Webcast and Conference Call to be Held at 4:30 p.m. EST on November 8, 2017

First Week of OTIC June 2018 Options Trading

First Week of OTIC June 2018 Options Trading

Investors in Otonomy Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

OTONOMY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The Firm

OTONOMY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Otonomy, Inc.

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.

TheStreet Quant Rating: D (Sell)